IONA® – Up, running and available on the NHS
​Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA estimates the risk that a fetus has any of Down’s, Edwards’ or Patau’s syndromes caused by a genetic abnormality. Although IONA is entering a competitive and litigious market, it has some advantages, is CE Marked and is the first to win a UK NHS contract. Premaitha is subject to distracting IP infringement claims but 1H’16 results showed early signs of commercial traction which are expected to accelerate herein. Also, Premaitha has signed a strategically important partnership with Thermo Fisher which adds considerable credibility.
Premaitha is an international molecular diagnostics group which utilize the DNA analysis technology to develop and regulatory approved genetic screening tests. Co.'s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women. Co.'s NIPT solutions include: regulated in vitro diagnostic product supply that enable clinical laboratories to establish their quality assured, regulated, NIPT analysis offering; clinical laboratory service, which available in Manchester, the U.K. and Taipei, Taiwan, where customers can send blood samples for NIPT analysis; and portfolio of technology, which has developed to support laboratories and healthcare to generate the NIPT analysis.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.